Advances in pyrimidine-like heterocyclic scaffolds: Innovative synthetic method for malic enzyme inhibition in pancreatic ductal adenocarcinoma (PDAC) - A comprehensive review.

Pancreatic cancer remains one of the most lethal cancers of the 21st century due to extensive metabolic reprogramming and a highly adaptable tumor microenvironment that fosters relentless growth and resistance to treatment. Molecular docking studies targeted on malic enzyme facilitate the discovery of possible inhibitors that interfere with pancreatic cancer metabolism. Understanding the molecular circuitry of this disease, especially through the use of heterocyclic frameworks that inhibit metabolic needs specific to cancer, has enabled targeted therapy. Pyrimidine and fused-pyrimidine structures have become unique scaffolds because they are very good at breaking down metabolic checkpoints that are important for tumors to stay alive. Pyrimidine derivatives are at the forefront of developing next-generation anticancer drugs because they inhibit the malic enzyme (ME), which is a key regulator of redox homeostasis and biosynthetic flux in pancreatic cancers. This review gives a full picture of the synthetic methods that make it easy to quickly change the structure of pyrimidine-based pharmacophores. Some of these strategies are old, like Vorbrüggen glycosylation and HATU-mediated peptide coupling. Others are new, like chalcone-guanidine cyclocondensation and modular multi-component protocols. Pyrimidine scaffolds are crucial elements of precision oncology, evidenced by data from preclinical and clinical studies that underscore the therapeutic translatability of targeting metabolic abnormalities in pancreatic cancer. Even though chemotherapy, targeted therapy, and immunotherapy have all become better in the last few years, treating pancreatic cancer is still challenging due to its late diagnosis, the drug resistance, and the fact that there aren't many suitable options for treatment. Apart from that, there are still some big problems to solve, like metabolic redundancy, isoform-selective ME inhibition, and the tumor microenvironment, which makes treatment harder. To overcome these challenges, the amalgamation of multi-pathway inhibition, AI-driven lead optimization, and nanotechnology-facilitated targeted delivery offers considerable promise. This review emphasizes the crucial function of pyrimidine scaffolds in revolutionizing the therapeutic strategy for pancreatic cancer, linking mechanistic understanding to practical drug discovery.